Celgene’s Revlimid (Lenalidomide) + Rituximab Receive FDA’s Approval for Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma in Adults

 Celgene’s Revlimid (Lenalidomide) + Rituximab Receive FDA’s Approval for Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma in Adults

Celgene’s Revlimid (Lenalidomide) + Rituximab Receive FDA’s Approval for Previously Treated Follicular Lymphoma or Marginal Zone Lymphoma in Adults

Shots:

  • The approval is based on P-III AUGMENT study results assessing Revlimid + Rituximab (R2) vs rituximab + PBO in patients with previously treated FL & MZL, following its PR designation
  • The P-III AUGMENT study results: mPFS (39.4 vs 14.1 mos.); improvement in OS; median follow-up time (28.3 mos.)
  • Revlimid is a thalidomide analog and is indicated in combination with rituximab, currently under EMA regulatory review for r/r FL & MZL with its sNDA submission to PMDA of R2 for the treatment of relapsed/refractory indolent B-cell NHL in Japan

Click here to read full press release/ article | Ref: Celgene | Image: Specialty Pharma Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post